Indication
BroPair Spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting ?? agonists.
Loading your page…
Loading your page…
Asthma
Marketing Authorisation Holder: Teva B.V.
EMA Authorisation: 26/03/2021
INN: salmeterol;fluticasone propionate
AI Drug & Interaction Analysis
Free account required
Ask Osler about BroPair Spiromax: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.